Unlike other forms of breast cancers, there are currently no effective targeted therapies for TNBCs due to the lack of an estrogen receptor (ER) or progesterone receptor (PR) and amplification of the HER2 receptor [5,6]. This evidence concerns the gene PGR and breast cancer.